This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Kenalog-40 Injection (2014-03-04)

Starting date:
March 4, 2014
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type II
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-38689

Recalled products

  1. Kenalog-40 Injection

Reason

This product may have been exposed to temperatures outside of the recommended storage requirements during their transport from CanadaDrugs.com to Canada Diagnostic Centres in Alberta, Canada. The safety and efficacy of these drugs may be impacted by the temperature excursion.

Note: only the units shipped from CanadaDrugs.com to Canada Diagnostics Centres in Alberta, Canada are affected, not the entire lots.

Depth of distribution

Distributed to Canada Diagnostic Centres in Alberta, Canada.

Note: all other units of these lots of Kenalog 40 mg/mL sold by Bristol-Myers Squibb Canada are not impacted by this recall.

Affected products

A. Kenalog-40 Injection

DIN, NPN, DIN-HIM
DIN 01999869
Dosage form

Suspension

Strength
  • Triamcinolone Acetonide, 40 mg/mL
Lot or serial number
  • 3J74513
  • 3H66288
  • 3L72817
  • 3G74417
  • 3E73787
Companies
Recalling Firm
CanadaDrugs.com LP
10 Terracon Place
Winnipeg
R2J 4G7
Manitoba
CANADA
Marketing Authorization Holder
Bristol-Myers Squibb Canada
2344 Boul. Alfred-Nobel, Suite 300
Montréal (Saint-Laurent)
H4S 0A4
Quebec
CANADA

Date modified: